 CAMBRIDGE, Mass., Oct. 01, 2021 GLOBE NEWSWIRE -- Codiak BioSciences, Inc. Nasdaq: CDAK, a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that three posters featuring preclinical data from its engExTM Platform programs will be presented during the 36th Annual Meeting of the Society for Immunotherapy of Cancer SITC 2021, which is being held virtually and in person in Washington, D.C. from November 10-14, 2021. 